Visual Detection of Fusion Genes by Ligation-Triggered Isothermal Exponential Amplification: A Point-of-Care Testing Method for Highly Specific and Sensitive Quantitation of Fusion Genes with a Smartphone

2019 ◽  
Vol 91 (19) ◽  
pp. 12428-12434 ◽  
Author(s):  
Hui Wang ◽  
Honghong Wang ◽  
Yuting Jia ◽  
Ruyan Sun ◽  
Weixiang Hong ◽  
...  
Keyword(s):  
Visual Detection ◽  
Point Of Care ◽  
Fusion Genes ◽  
Point Of Care Testing ◽  
Testing Method

Detection of microRNA: A Point-of-Care Testing Method Based on a pH-Responsive and Highly Efficient Isothermal Amplification

2017 ◽  
Vol 89 (12) ◽  
pp. 6631-6636 ◽  
Author(s):  
Chang Feng ◽  
Xiaoxia Mao ◽  
Hai Shi ◽  
Bing Bo ◽  
Xiaoxia Chen ◽  
...  
Keyword(s):  
Point Of Care ◽  
Isothermal Amplification ◽  
Ph Responsive ◽  
Point Of Care Testing ◽  
Testing Method ◽  
Highly Efficient

Aptamer based Diagnosis: A Cost Effective and Suitable Point of Care Testing Method Against SARS Coronavirus-2 (SARs-CoV-2) and Other Rapidly Spreading Diseases

2021 ◽  
Vol 10 ◽  
Author(s):  
Vivek Kumar ◽  
Gulab Singh Yadav ◽  
Basu Dev Banerjee
Keyword(s):  
Point Of Care ◽  
Cost Effective ◽  
Sars Coronavirus ◽  
Point Of Care Testing ◽  
Testing Method ◽  
Efficient Detection ◽  
The Mean ◽  
Polymerase Chain ◽  
New Generation ◽  
Spreading Disease

: The current SARS coronavirus-2 (SARs-CoV-2) pandemic has raised serious concerns regarding the inefficiency of available diagnostic method for rapid and efficient detection of the disease. It is agreed widely that Real time Polymerase Chain Reaction (RT-PCR) and antibody based assays have several limitations that did not help much in preventing exponential spread of the disease in short span of period. Unarguably, the world needs “new-generation diagnostic intervention(s)” against rapidly spreading disease like SARS CoV-2. We have presented aptamer based strategy as a possible point of care testing for diagnosis of the disease. It has several advantages over current tools available and can be used for efficient combating by the mean of quick cost effective and much more accurate diagnostic against the enigmatic SARS CoV-2 disease and similar pandemic which world may possibly encounter in the future

Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method

2004 ◽  
Vol 42 (10) ◽  
Author(s):  
Simona Storti ◽  
Concetta Prontera ◽  
Michele Emdin ◽  
Claudio Passino ◽  
Paola Prati ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Point Of Care ◽  
Clinical Results ◽  
Analytical Performance ◽  
Point Of Care Testing ◽  
Testing Method ◽  
Significant Bias ◽  
Microparticle Enzyme Immunoassay ◽  
Method R

AbstractThe aim of this study was to evaluate the analytical performance of a recently available immunoassay for brain natriuretic peptide (BNP), based on microparticle enzyme immunoassay (MEIA, AxSYM System, Abbott Laboratories), whose analytical characteristics and clinical results were compared with those of a point of care testing (POCT) method (TRIAGE system, Biosite Diagnostics). The within-run and total imprecision of the MEIA system were 18.4% and 19.8% at 21 ng/l, 8.0% and 14.8% at 183 ng/l, and 5.7% and 14.0% at 319 ng/l, respectively. The detection limit of the MEIA system was tested by repeatedly measuring (n = 20) the 0 calibrator in four different runs; a mean +3 SD value of 5.6 ± 4.8 ng/l (range 1.8–12.6 ng/l) was obtained. A close linear relationship (MEIA = –22.5 + 1.71 POCT method, R = 0.950, n = 296) was found (BNP concentration: 5–5500 ng/l), with a significant bias (mean difference: 164.8 ng/l, p < 0.0001). Mean BNP concentration measured in 94 reference subjects (57 women and 37 men; mean age 43.5 ± 14.0 years) was higher with MEIA than POCT, (25.9 ± 32.7 ng/l vs. 11.7 ± 8.9 ng/l, p < 0.0001). The same trend was observed also in 202 cardiac patients (620.6 ± 1082.2 ng/l vs. 386.1 ± 594.5 ng/l, p < 0.0001). Our data suggest that MEIA and POCT have quite similar analytical performance but different clinical results. Then, different reference values, as well as cut-off values, should be taken into account for the clinical use of these two immunoassays.

scholarly journals Comparison of a Fully Automated Immunoassay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide

2005 ◽  
Vol 51 (7) ◽  
pp. 1274-1276 ◽  
Author(s):  
Concetta Prontera ◽  
Simona Storti ◽  
Michele Emdin ◽  
Claudio Passino ◽  
Luc Zyw ◽  
...  
Keyword(s):  
Natriuretic Peptide ◽  
Point Of Care ◽  
Point Of Care Testing ◽  
Testing Method ◽  
Automated Immunoassay
Sign in / Sign up

Export Citation Format

Share Document